Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Garetosmab

COURAGE

Regeneron · Phase 2 · Active, not recruiting · Enrollment 1005

NCT06299098

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebon/rn/rn/rn/r
Trevogrumabn/rn/rn/rn/r
Arm A0n/rn/rn/rn/r
Arm A1n/rn/rn/rn/r
Arm B0n/rn/rn/rn/r
Arm B1n/rn/rn/rn/r
Arm C0n/rn/rn/rn/r
Arm C1n/rn/rn/rn/r
Arm D0n/rn/rn/rn/r
Arm D1n/rn/rn/rn/r
Arm 1n/rn/rn/rn/r
Arm 2n/rn/rn/rn/r
Arm 3n/rn/rn/rn/r

Not shown

  • Placebo: endpoint not reported
  • Trevogrumab: endpoint not reported
  • Arm A0: endpoint not reported
  • Arm A1: endpoint not reported
  • Arm B0: endpoint not reported
  • Arm B1: endpoint not reported
  • Arm C0: endpoint not reported
  • Arm C1: endpoint not reported
  • Arm D0: endpoint not reported
  • Arm D1: endpoint not reported
  • Arm 1: endpoint not reported
  • Arm 2: endpoint not reported
  • Arm 3: endpoint not reported